After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Kyverna Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Kyverna Therapeutics Inc is $507.31M. A total of 2.22 million shares were traded on the day, compared to an average of 1.37M shares.
In the most recent transaction, SEIDENBERG BETH C bought 133,333 shares of KYTX for 7.50 per share on Dec 18 ’25. After the transaction, the Director now owns 869,317 company shares. In a previous transaction on Dec 18 ’25, Westlake BioPartners Opportuni bought 133,333 shares at 7.50 per share. KYTX shares that 10% Owner owns now total 869,317.
Among the insiders who sold shares, Walker Karen Marie disposed of 23,998 shares on Dec 15 ’25 at a per-share price of $12.20. This resulted in the Chief Technology Officer holding 22,636 shares of KYTX after the transaction. In another insider transaction, KAREN WALKER bought 23,998 shares at $8.78 per share on Dec 15 ’25.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, KYTX has a high of $13.67 and a low of $1.78.
As of this writing, KYTX has an earnings estimate of -$0.91 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.81 per share and a lower estimate of -$1.15. The company reported an EPS of -$0.88 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. KYTX’s latest balance sheet shows that the firm has $76.07M in Cash & Short Term Investments as of fiscal 2021. There were $5.55M in debt and $15.93M in liabilities at the time. Its Book Value Per Share was $3.47, while its Total Shareholder’s Equity was -$46.25M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KYTX is Buy with a score of 4.71.
